Joel AG van Roon

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. ncbi Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression
    Angela Bikker
    Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands
    Ann Rheum Dis 71:1934-41. 2012
  2. ncbi Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis
    Manon C Zweers
    Rheumatology and Clinical Immunology, University Medical Center Utrecht, F02, 127, 3508 GA Utrecht, The Netherlands
    Arthritis Res Ther 13:239. 2011
  3. ncbi IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα
    Angela Bikker
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Rheumatology (Oxford) 51:996-1005. 2012
  4. ncbi Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity
    A Bikker
    UMC Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands
    Ann Rheum Dis 71:1027-33. 2012
  5. ncbi Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction
    Angela Bikker
    Dept of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands
    Curr Pharm Des 18:2347-56. 2012
  6. ncbi Numbers of CD25+Foxp3+ T cells that lack the IL-7 receptor are increased intra-articularly and have impaired suppressive function in RA patients
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
    Rheumatology (Oxford) 49:2084-9. 2010
  7. ncbi Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Ann Rheum Dis 66:664-9. 2007
  8. ncbi Interleukin-7 induced immunopathology in arthritis
    S A Y Hartgring
    Rheumatology and Clinical Immunology F02 127, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Ann Rheum Dis 65:iii69-74. 2006
  9. ncbi Diversity of regulatory T cells to control arthritis
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Best Pract Res Clin Rheumatol 20:897-913. 2006
  10. ncbi Role of interleukin-7 in degenerative and inflammatory joint diseases
    Joel A G van Roon
    Arthritis Res Ther 10:107. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression
    Angela Bikker
    Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands
    Ann Rheum Dis 71:1934-41. 2012
    ..To investigate whether the immunomodulatory capacities of leflunomide are associated with clinical efficacy in the treatment of primary Sjögren's syndrome (SS) in a phase II pilot study...
  2. ncbi Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis
    Manon C Zweers
    Rheumatology and Clinical Immunology, University Medical Center Utrecht, F02, 127, 3508 GA Utrecht, The Netherlands
    Arthritis Res Ther 13:239. 2011
    ..Can celecoxib be considered a disease-modifying osteoarthritic drug? In this review, these direct effects of celecoxib on cartilage, bone, and synoviocytes in OA treatment are discussed...
  3. ncbi IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα
    Angela Bikker
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Rheumatology (Oxford) 51:996-1005. 2012
    ....
  4. ncbi Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity
    A Bikker
    UMC Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands
    Ann Rheum Dis 71:1027-33. 2012
    ....
  5. ncbi Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction
    Angela Bikker
    Dept of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands
    Curr Pharm Des 18:2347-56. 2012
    ....
  6. ncbi Numbers of CD25+Foxp3+ T cells that lack the IL-7 receptor are increased intra-articularly and have impaired suppressive function in RA patients
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
    Rheumatology (Oxford) 49:2084-9. 2010
    ..To investigate numbers and function of CD25(+) regulatory T cells (Tregs) that lack IL-7 receptor (CD127) expression in RA...
  7. ncbi Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Ann Rheum Dis 66:664-9. 2007
    ..In addition, the effect of TNFalpha blockade on IL7 activity and on IL7 levels was studied...
  8. ncbi Interleukin-7 induced immunopathology in arthritis
    S A Y Hartgring
    Rheumatology and Clinical Immunology F02 127, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Ann Rheum Dis 65:iii69-74. 2006
    ..Together this suggests that IL-7 is an important cytokine in several rheumatic conditions, capable of inducing inflammation and immunopathology. Thus it may be an important target for immunotherapy...
  9. ncbi Diversity of regulatory T cells to control arthritis
    Joel A G van Roon
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Best Pract Res Clin Rheumatol 20:897-913. 2006
    ....
  10. ncbi Role of interleukin-7 in degenerative and inflammatory joint diseases
    Joel A G van Roon
    Arthritis Res Ther 10:107. 2008
    ..This indicates that IL-7, indirectly via immune activation, but also by a direct action on cartilage, contributes to joint destruction in rheumatic diseases...
  11. ncbi Activating and inhibitory Fc gamma receptors in rheumatoid arthritis: from treatment to targeted therapies
    Joel A G van Roon
    Arthritis Res Ther 9:106. 2007
    ..This progress offers an opportunity to study modulation of Fc gammaR balance and could stimulate development of Fc gammaR-directed immunotherapy...